These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20124288)

  • 1. Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK.
    Kirby A; Graham R; Williams NJ; Wootton M; Broughton CM; Alanazi M; Anson J; Neal TJ; Parry CM
    J Antimicrob Chemother; 2010 Apr; 65(4):721-4. PubMed ID: 20124288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.
    Garnier F; Chainier D; Walsh T; Karlsson A; Bolmström A; Grelaud C; Mounier M; Denis F; Ploy MC
    J Antimicrob Chemother; 2006 Jan; 57(1):146-9. PubMed ID: 16286482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of reduced susceptibility to glycopeptides among methicillin-resistant Staphylococcus aureus isolates from patients in Ireland and evaluation of agar screening methods for detection of heterogeneously glycopeptide-intermediate S. aureus.
    Fitzgibbon MM; Rossney AS; O'Connell B
    J Clin Microbiol; 2007 Oct; 45(10):3263-9. PubMed ID: 17687008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Endemic heteroresistant glycopeptide intermediate Staphylcoccus aureus (hGISA) comprising unrelated clonal types and not associated with vancomycin therapy].
    Lecaillon E; Gueudet P; Wooton M; Walsh TR; Macgowan AP; Jones ME
    Pathol Biol (Paris); 2002 Nov; 50(9):525-9. PubMed ID: 12490414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of the Etest GRD for detecting Staphylococcus aureus with reduced susceptibility to glycopeptides in cystic fibrosis patients.
    Filleron A; Chiron R; Reverdy ME; Jean-Pierre H; Dumitrescu O; Aleyrangues L; Counil F; Jumas-Bilak E; Marchandin H
    Eur J Clin Microbiol Infect Dis; 2012 Apr; 31(4):599-604. PubMed ID: 21904858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).
    Voss A; Mouton JW; van Elzakker EP; Hendrix RG; Goessens W; Kluytmans JA; Krabbe PF; de Neeling HJ; Sloos JH; Oztoprak N; Howe RA; Walsh TR
    Ann Clin Microbiol Antimicrob; 2007 Sep; 6():9. PubMed ID: 17892555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands.
    Van Griethuysen A; Van 't Veen A; Buiting A; Walsh T; Kluytmans J
    J Clin Microbiol; 2003 Jun; 41(6):2487-91. PubMed ID: 12791870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative activities of daptomycin and several agents against staphylococcal blood isolates. Glycopeptide tolerance.
    Picazo JJ; Betriu C; Rodríguez-Avial I; Culebras E; López-Fabal F; Gómez M;
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):373-9. PubMed ID: 21683269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.
    Yusof A; Engelhardt A; Karlsson A; Bylund L; Vidh P; Mills K; Wootton M; Walsh TR
    J Clin Microbiol; 2008 Sep; 46(9):3042-7. PubMed ID: 18596146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the effectiveness of common hospital hand disinfectants against methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus, and heterogeneous glycopeptide-intermediate S. aureus.
    Wootton M; Walsh TR; Davies EM; Howe RA
    Infect Control Hosp Epidemiol; 2009 Mar; 30(3):226-32. PubMed ID: 19199533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides.
    Wootton M; MacGowan AP; Walsh TR; Howe RA
    J Clin Microbiol; 2007 Feb; 45(2):329-32. PubMed ID: 17108069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Fourier transform infrared spectroscopy for the rapid identification of glycopeptide-intermediate Staphylococcus aureus.
    Amiali NM; Mulvey MR; Berger-Bächi B; Sedman J; Simor AE; Ismail AA
    J Antimicrob Chemother; 2008 Jan; 61(1):95-102. PubMed ID: 17962217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decline of EMRSA-16 amongst methicillin-resistant Staphylococcus aureus causing bacteraemias in the UK between 2001 and 2007.
    Ellington MJ; Hope R; Livermore DM; Kearns AM; Henderson K; Cookson BD; Pearson A; Johnson AP
    J Antimicrob Chemother; 2010 Mar; 65(3):446-8. PubMed ID: 20035019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular epidemiology of methicillin-resistant Staphylococcus aureus from bacteraemia in northern Italy.
    Aschbacher R; Pichon B; Wootton M; Davies L; Binazzi R; Pike R; Ganner M; Hill R; Pagani E; Agreiter I; Mian P; Larcher C; Kearns A
    Infez Med; 2012 Dec; 20(4):256-64. PubMed ID: 23299065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains.
    Wootton M; Bennett PM; MacGowan AP; Walsh TR
    J Antimicrob Chemother; 2005 Nov; 56(5):944-7. PubMed ID: 16157619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07.
    Reynolds R; Hope R; Warner M; MacGowan AP; Livermore DM; Ellington MJ;
    J Antimicrob Chemother; 2012 Dec; 67(12):2912-8. PubMed ID: 22899805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.
    Diederen BM; van Duijn I; Willemse P; Kluytmans JA
    Antimicrob Agents Chemother; 2006 Sep; 50(9):3189-91. PubMed ID: 16940127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycopeptide intermediate Staphylococcus aureus and prevalence of the luk-PV gene in clinical isolates, in Northern Lebanon.
    El Ayoubi MD; Hamze M; Mallat H; Achkar M; Dabboussi F
    Med Mal Infect; 2014 May; 44(5):223-8. PubMed ID: 24835167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of an outbreak of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in a French hospital.
    Mallaval FO; Carricajo A; Delavenna F; Recule C; Fonsale N; Manquat G; Raffenot D; Rogeaux O; Aubert G; Tous J
    Clin Microbiol Infect; 2004 May; 10(5):459-61. PubMed ID: 15113326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
    Betts JW; Abdul Momin HF; Phee LM; Wareham DW
    J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.